DS
ALGS icon

David Shaw’s Aligos Therapeutics ALGS Stock Holding History

David Shaw’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Buy
66,463
+55,485
+505% +$343K ﹤0.01% 4301
2026
Q1 		$81.6K Buy
+10,978
New +$83.3K ﹤0.01% 4302
2022
Q4 		– Sell
-1,263
Closed -$35K – 4837
2022
Q3 		$35K Sell
1,263
-4,932
-80% -$164K ﹤0.01% 4732
2022
Q2 		$187K Buy
6,195
+5,364
+645% +$182K ﹤0.01% 4568
2022
Q1 		$45K Buy
+831
New +$66.5K ﹤0.01% 5161

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's ALGS Position: Q2 2026 in Review

David Shaw increased its Aligos Therapeutics (ALGS) stake by 505% in Q2 2026, buying an estimated $343K and bringing the position to 66,463 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #4301.

David Shaw first reported a position in ALGS in Q1 2022 and has held it in 5 quarters since. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • David Shaw held 66,463 shares of Aligos Therapeutics worth $383K as of Q2 2026.
  • David Shaw bought 55,485 Aligos Therapeutics shares in Q2 2026, an estimated $343K.
  • Aligos Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4301 holding.
  • David Shaw first reported a position in Aligos Therapeutics in Q1 2022 and has held it in 5 quarters since.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.